Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/08/26	USD 1.670	0.00%	20,870
26/08/26	USD 1.670	+4.37%	128,311
25/08/26	USD 1.600	+3.23%	122,090
24/08/26	USD 1.550	-0.64%	133,883
21/08/26	USD 1.560	-4.29%	244,126

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.670USD

Average target price

26.00USD

Spread / Average Target

+1,456.89%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq 01:57:48 28/08/26 am AEST			5-day change	1st Jan Change
1.670 ^USD	0.00%		+2.45%	-8.24%

20/08	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI
18/08	Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop	CI

Market Cap	8M 6.87M 6.43M 5.89M 11.09M 764M 11.12M 76.15M 29.77M 385M 30.04M 29.39M 1.27B	P/E 2027 *	-1.59x	P/E 2028 *	-1.92x
Enterprise Value	8M 6.87M 6.43M 5.89M 11.09M 764M 11.12M 76.15M 29.77M 385M 30.04M 29.39M 1.27B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	97.32%	Yield 2027 *	-	Yield 2028 *	-

20/08	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI
18/08	Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop	CI
05/08	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending	CI
23/07	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026	CI
22/07	Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt	CI
22/07	Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026	CI
07/04	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001	CI
26/03	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001	CI
17/03	Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	CI
16/03	Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital	RE
12/03	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026	CI
07/03	Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stock - SEC filing	RE
10/12	Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2025	CI

12/04/23	Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	MT
28/12/21	Ascendiant Capital Adjusts Price Target on Alzamend Neuro to $8.25 From $8, Maintains Buy Rating	MT
02/10/21	Alzamend Neuro : Ascendiant Capital Initiates Alzamend Neuro at Buy Rating With $8 Price Target	MT

Alzamend Neuro, Inc. Stock

Stocks

ALZN

US02262M6057

Biotechnology & Medical Research

Valuation : Alzamend Neuro, Inc.

Chart: Alzamend Neuro, Inc.

Latest news : Alzamend Neuro, Inc.

Analysts' recommendations : Alzamend Neuro, Inc.

Press Releases : Alzamend Neuro, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Alzamend Neuro, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

20/08	Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC	PR
18/08	Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain	PR
23/07	Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)	PU
07/04	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital	PU
26/03	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions	PR

1 day	-0.90%
1 week	+2.45%
Current month	+27.48%
1 month	+24.63%
3 months	+45.22%
6 months	-16.92%
Current year	-8.24%

1 week	1.41	1.67
1 month	1.26	1.67
Current year	0.84	2.54
1 year	0.84	2.68
3 years	0.84	403.11
5 years	0.84	4,819.5
10 years	0.84	45,292.48

Manager	Title	Age	Since
Stephan Jackman CEO	Chief Executive Officer	50	20/11/2018
David Katzoff DFI	Director of Finance/CFO	64	05/08/2022
Henry Nisser LAW	General Counsel	57	01/05/2019

Director	Title	Age	Since
Todd Ault CHM	Chairman	56	26/02/2016
William Horne CHM	Chairman	57	01/06/2021
Stephan Jackman BRD	Director/Board Member	50	01/09/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/7/26	HYPERSCALE DATA, INC.	Free	Company	7,500	0.1565%
31/7/26	Todd Ault	Other	Founder	0	0%
31/7/26	HYPERSCALE DATA, INC.	Free	Company	7,500	0.1565%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZAMEND NEURO, INC.	0.00%	+2.45%	-32.11%	-99.56%	8M
LONZA GROUP AG	+0.10%	+0.44%	+2.80%	+23.74%	50.96B
REVOLUTION MEDICINES, INC.	+2.13%	+4.14%	+479.65%	+583.51%	46.18B
BEONE MEDICINES AG	-0.68%	+0.87%	+24.07%	+84.26%	42.73B
IQVIA HOLDINGS INC.	+0.91%	+2.87%	+39.52%	+18.77%	43.04B
CELLTRION, INC.	-2.27%	-3.02%	+14.22%	+51.50%	33.48B
MEDPACE HOLDINGS, INC.	-0.56%	+0.44%	+29.95%	+135.17%	17.28B
ASCENDIS PHARMA A/S	-0.59%	-2.21%	-	-	16.43B
EUROFINS SCIENTIFIC SE	+0.25%	+0.25%	+12.03%	+28.88%	14.73B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.00%	+3.46%	+85.21%	+51.70%	14.09B
Average	+0.11%	+2.18%	+72.81%	+97.55%	27.89B
Weighted average by Cap.	+0.30%	+1.16%	+104.35%	+143.91%

	2027 *	2028 *
Net sales	-	-
Net income	-10.8M -9.27M -8.68M -7.95M -14.97M -1.03B -15.01M -103M -40.18M -520M -40.55M -39.67M -1.72B	-10.8M -9.27M -8.68M -7.95M -14.97M -1.03B -15.01M -103M -40.18M -520M -40.55M -39.67M -1.72B
Net Debt	-	-